Sustained effects of single doses of classical psychedelics in humans

Sustained effects of single doses of classical psychedelics in humans

Knudsen, G.M. (2022) Abstract The serotonergic classical psychedelics include compounds that primarily activate the brain’s serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of...
October 04, 2022 — Tyler Ozkan
Response of cluster headache to psilocybin and LSD

Response of cluster headache to psilocybin and LSD

The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks;...
August 31, 2022 — Tyler Ozkan
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s...
August 26, 2022 — Tyler Ozkan
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Major depressive disorder (MDD) is a substantial public health concern, affecting more than 300 million individuals worldwide. Depression is the number one cause of disability, and the relative risk of...
August 24, 2022 — Tyler Ozkan